Benlysta is a human monoclonal antibody that was approved for the treatment of lupus in adults by the U.S. Food and Drug Administration (FDA) in 2011 and for lupus nephritis in adults in 2020.

The 200mg single-dose prefilled autoinjector allows pediatric patients to receive SLE treatment at home via SC administration. The Food and Drug Administration (FDA) has approved Benlysta (belimumab) ...

Benlysta is an immunosuppressant medication that can lower the amount of antibodies your immune system produces. This makes it effective in managing different forms of lupus. Benlysta works by ...

MONDAY, June 30, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved an autoinjector of Benlysta (belimumab) for subcutaneous injection in patients ≥5 years of age with active ...

The U.S. Food and Drug Administration has approved GlaxoSmithKline's 200-mg subcutaneous route of administration of Benlysta (belimumab) for patients 5 years of age and older with active systemic ...

The U.S. Food & Drug Administration (FDA) has granted approval for a novel and less invasive belimumab (Benlysta®) treatment for children with systemic lupus erythematosus (SLE) ages five years and ...

Belimumab autoinjector is now approved and available for pediatric patients with lupus nephritis. The US Food and Drug Administration (FDA) has approved the belimumab 200 mg/mL autoinjector for ...

Please provide your email address to receive an email when new articles are posted on . Children treated with belimumab were more likely to achieve primary efficacy renal response vs. standard ...

The US Food and Drug Administration (FDA) has approved Benlysta (belimumab) autoinjector for patients aged 5 years or older with active systemic lupus erythematosus (SLE) on standard therapy. This is ...

The 200-mg subcutaneous injection is for children 5 years and older. HealthDay News — The US Food and Drug Administration has approved a 200 mg subcutaneous route of administration of Benlysta ...